Package Insert: Information for the Patient
Risedronate Farma Qualigen75 mg Film-Coated Tablets
Risedronate sodium
Read this entire package insert carefully before starting to take this medication, as it contains important information for you.
-This medication has been prescribed for you only, and you should not give it to others even if they have the same symptoms as you, as it may harm them.
1. What Risedronate Farma Qualigen 75 mg is and what it is used for
2. What you need to know before starting to take Risedronate Farma Qualigen 75 mg
3. How to take Risedronate Farma Qualigen 75 mg
4. Possible side effects
5. Storage of Risedronate Farma Qualigen 75 mg
6. Contents of the pack and additional information
Risedronato Farma Qualigen 75 mg
Risedronato Farma Qualigen 75 mg belongs to a group of non-hormonal medications called bisphosphonates, which are used for the treatment of bone diseases. It acts directly on the bones, strengthening them and, therefore, reduces the probability of fractures.
The bone is a living tissue. Old bone in the skeleton is constantly being renewed and replaced by new bone.
Postmenopausal osteoporosis is a condition that appears in women after menopause when bones begin to weaken, become more fragile, and are more likely to fracture after a fall or twist.
The most likely bone fractures are those of the vertebrae, hip, and wrist, although they can occur in any bone in the body. Fractures related to osteoporosis can also cause back pain, loss of height, and a curved back. Many patients with osteoporosis do not have symptoms and may not even know they have it.
What is Risedronato Farma Qualigen 75 mg used for
For the treatment of osteoporosis in women after menopause.
Do not take Risedronato Farma Qualigen 75mg
Warnings and precautions
Consult your doctor or pharmacist before starting to take Risedronato Farma Qualigen 75mg
?If you cannot remain in an upright position (sitting or standing) for at least 30 minutes.
?If you have bone or mineral metabolism disorders (for example, vitamin D deficiency, parathyroid hormone alterations, which cause low blood calcium levels).
?If you have had problems with the esophagus (the tube that connects the mouth to the stomach) in the past. For example, you may have had difficulty swallowing food or if you have been previously informed that you haveBarrett's esophagus (a disease associated with changes in the cells of the lower part of the esophagus).
?If you have had or have jaw pain, swelling, or numbness, or a “heavy feeling in the jaw” or if a tooth has moved.
Your doctor will advise you what to do if you take Risedronato Farma Qualigen 75 mg and have any of the problems mentioned above.
Children and adolescents
Risedronate sodium is not recommended for children under 18 years of age due to a lack of safety and efficacy data.
Taking Risedronato Farma Qualigen 75mg with other medications
Medications that contain any of the following substances reduce the effect of Risedronato Farma Qualigen 75 mg if taken at the same time:
Take these medications at least 30 minutes after taking your Risedronato Farma Qualigen 75 mg tablet.
Inform your doctor or pharmacist if you are taking or using, have taken or used recently, or may need to take or use other medications.
Taking Risedronato Farma Qualigen 75mg with food and drinks
It is very important that you DO NOT take your Risedronato Farma Qualigen 75mg tablet with food or drinks (other than water) so that it can work correctly. In particular, do not take this medication at the same time as dairy products (such as milk) as they contain calcium (see section 2, “Taking Risedronato Farma Qualigen 75mg with other medications”).
Take food and drinks (other than water) at least 30 minutes after taking your Risedronato Farma Qualigen 75 mg tablet.
Pregnancy and breastfeeding
DO NOT take Risedronato Farma Qualigen 75mg if you may be pregnant, if you are pregnant, or if you plan to become pregnant (see section 2, “Do not take Risedronato Farma Qualigen 75mg”). The risk associated with the use of risedronate sodium (active ingredient of Risedronato Farma Qualigen 75mg) in pregnant women is unknown.
DO NOT take Risedronato Farma Qualigen 75mg if you are breastfeeding (see section 2, “Do not take Risedronato Farma Qualigen 75mg”).
Risedronato Farma Qualigen 75mg should only be used to treat postmenopausal women.
Driving and operating machinery
Risedronato Farma Qualigen 75mg has no known effect on the ability to drive and use machines.
Risedronato Qualigen Farma contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
Usual dose:
Risedronato Farma Qualigen 75mg tablets should be taken TWO days in a row per MONTH, and always on the SAME two days of each month (for example, the 1st and 2nd days or 15th and 16th of the month).
Choose the TWO consecutive days that best fit your schedule to take this medication. Take ONE Risedronato Farma Qualigen 75mg tablet in the morning on the first chosen day. Take the SECOND tablet in the morning on the following day.
Repeat every month maintaining the same two consecutive days. To help you remember when to take the tablets again, you can mark it on your calendar with a pen or stickers.
WHEN to take the Risedronato Farma Qualigen 75 mg tablet
Take the Risedronato Farma Qualigen 75mg tablet at least 30 minutes before the first meal, drink (except tap water) or other medication of the day.
HOW to take the Risedronato Farma Qualigen 75 mg tablet
Your doctor will indicate if you should take calcium and vitamin supplements, if the amount you take in your diet is not sufficient.
IF you take MORE Risedronato Farma Qualigen 75mg than you should
If you or someone else has accidentally taken more Risedronato Farma Qualigen 75mg tablets than prescribed, drink aglass of milkfull andconsult your doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service (phone 91 562 04 20), indicating the medication and the amount taken.
IF you FORGET to take Risedronato Farma Qualigen 75mg
You forgot | When | What to do |
1st and 2nd tablets | More than 7 days before the next monthly dose | Take the 1st tablet the next morning and the 2nd tablet the morning after |
The next monthly dose is within the next 7 days | Do not take the tablets you forgot | |
2nd tablet only | More than 7 days before the next monthly dose | Take the 2nd tablet the next morning |
The next monthly dose is within the next 7 days | Do not take the tablet you forgot | |
Next month, take the tablets again in the normal way. |
In any case:
IF you INTERRUPT the treatment with Risedronato Farma Qualigen 75mg
If you stop taking the treatment, you may start losing bone mass. Please consult your doctor before deciding to interrupt the treatment.
If you have any other questions about the use of this medication, ask your doctoror pharmacist.
Like all medications, Risedronate Farma Qualigen 75 mg may cause side effects, although not everyone will experience them.
Stop taking Risedronate and seek medical attention immediatelyif you experience any of the following symptoms:
•Severe allergic reaction symptoms, such as:
-Swelling of the face, lips, tongue, throat, or neck
-Difficulty swallowing
-Difficulty breathing
-Rash, skin eruption
•Severe skin reactions, such as:
-Appearance of blisters on the skin, mouth, eyes, and other moist areas of the body (Stevens-Johnson syndrome)
-Red, palpable spots on the skin (leucocytoclastic vasculitis)
-Red rash on many parts of the body and/or loss of the outer layer of the skin (toxic epidermal necrolysis).
Inform your doctor quicklyif you experience any of the following side effects:
However, in clinical studies, other side effects observed were generally mild and did not cause patients to interrupt treatment.
Frequent side effects(may affect up to 1 in 10 people)
Uncommon side effects(may affect up to 1 in 100 people)
Rare side effects(may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Rarely, at the beginning of treatment, some patients may experience a decrease in blood calcium and phosphate levels. These changes are usually small and do not cause symptoms.
During post-marketing use, the following side effects have been reported (frequency not known):
•Hair loss
•Liver disorders, in some cases severe
•Inflammation of small blood vessels
Atypical femoral fractures, which can occur in rare cases, especially in patients on long-term treatment for osteoporosis. Inform your doctor if you experience pain, weakness, or discomfort in the thigh, hip, or groin, as these may be early signs of a possible femoral fracture.
If you experience side effects, consult your doctor, pharmacist, or nurse,even if they are side effects that do not appear in this leaflet.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. This will help protect the environment.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus.
You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: www.notificaRAM.es.
Composition of Risedronate Farma Qualigen 75mg
- The active ingredient is risedronate sodium. Each tablet contains 75mg of risedronate sodium (equivalent to 69.6mg of risedronic acid).
- The other components (excipients) are:
Tablet core: microcrystalline cellulose, crospovidone, magnesium stearate.
Coating:Opadry II pink [polyvinyl alcohol, talc, macrogol 3350, titanium dioxide (E171), iron oxide red (E172)].
Appearance of the product and contents of the packaging
Risedronate Farma Qualigen 75mg film-coated tablets are film-coated, oblong, and pink. They are presented in a blister pack containing 2, 4, 6, or 8 tablets. Some pack sizes may only be marketed.
Marketing authorization holder
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69. 08970 Sant Joan Despí, Barcelona
Spain
Responsible for manufacturing:
Bluepharma Industria Farmaceutica S.A.Sâo Martinho do Bispo
3045-016 Coimbra
Portugal
This medicine is authorized in the member states of the European Economic Area with the following names:
FranceRisedronate BGR 75 mg, coated tablet
GermanyRisedronat AL 75 mg Filmtabletten
GreeceBondamax 75
SpainRisedronate Farma Qualigen 75 mg film-coated tablets EFG
ItalyRisedronate DOC
NetherlandsRisedrinaatnatrium BGR 75 mg, film-coated tablets
PortugalRisedronate sodium BGR
This leaflet has been revised in:December 2020
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.